Panagora Asset Management’s Prelude Therapeutics PRLD Stock Holding History

Panagora Asset Management’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Buy	+47,574	New	+$207K	﹤0.01%	1067

Other funds holding PRLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Panagora Asset Management's PRLD Position: Q2 2026 in Review

Panagora Asset Management opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 47,574 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #1067 among its holdings.

17 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

Panagora Asset Management held 47,574 shares of Prelude Therapeutics worth $254K as of Q2 2026.
Prelude Therapeutics was a new Panagora Asset Management position in Q2 2026.
Prelude Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #1067 holding.
17 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.